Henry Stewart Talks

The Biomedical & Life Sciences Collection

Online Seminars By Leading World Experts
Search

Talk: Gene therapy and virotherapy in the treatment of cancer (46 min)

 Loading...

This talk is not yet available, however should be within a few days.

We apologize for the inconvenience.

- Henry Stewart Talks

X Navigable Slide Index
  1. Introduction
  2. Lecture structure
  3. Hallmarks of cancer
  4. Colorectal carcinoma
  5. Caecal polyps at different stages of development
  6. The challenge faced by targeted chemotherapy
  7. Gene therapy providing cells with new ways to die
  8. Advanced cancer is a bodywide disease
  9. Systemic delivery of cancer gene therapy
  10. Blood supply to the liver vs. the tumour
  11. The keys to success with gene therapy
  12. Adenovirus
  13. Cancer gene therapy: strategies
  14. P53 supplementation gene therapy
  15. Tumour necrosis factor as an anticancer agent
  16. TNFerade
  17. TNFerade: phase 1 trial
  18. TNFerade: phase 3 trial
  19. Virotherapy
  20. Lytic viruses: candidates for virotherapy
  21. Why use oncolytic viruses?
  22. Clinical trials with wild type viruses
  23. Why tumours are permissive for wild type viruses
  24. Interferon normally defends cells against viruses
  25. Viruses turn off PKR to make cell “permissive”
  26. Tumours with Ras mutation have inactivated PKR
  27. Mechanism of tumour selectivity of Reovirus
  28. Options for virotherapy
  29. Adenovirus structure & mechanism of infection
  30. The ‘Onyx virus’ (015) lacks E1B55kD
  31. ONYX-015 - a replication selective adenovirus
  32. Oncolytic virotherapy with an Adenovirus (1)
  33. Oncolytic virotherapy with an Adenovirus (2)
  34. Oncolytic virotherapy: TEM image
  35. Oncolytic virotherapy: approved in China
  36. ColoAd1: virotherapy designed by bioselection
  37. Genetic characterisation of ColoAd1
  38. ColoAd1 is active in whole human blood
  39. Viruses can produce therapeutic proteins
  40. Targeted expression of biological therapies
  41. Oncolytic vaccinia virus (Jx594)
  42. Activity of mutant virus in normal cells
  43. Activity of mutant vaccinia virus in tumour cells
  44. Clinical trial of Jx594 in liver cancer
  45. OncoVEX GM-CSF
  46. Phase 3 Talimogene Laherparepvec (T-VEC) trial
  47. Future of cancer virotherapy
  48. END
1 2 3

We hope you have enjoyed this free, full length talk

  • Would you like to recommend that your librarian or other responsible officer takes out a subscription to The Biomedical & Life Sciences Collection?
  • Would you like to apply for a free trial of the entire Biomedical & Life Sciences Collection?
Recommend to Librarian       Apply for Free Trial       Replay Talk

SHARE THIS TALK

Email via Local Program (e.g. Outlook) Email via the Web Share with Facebook Tweet on Twitter Share with Gmail Share with VKontakte Share with LinkedIn More

DETAILED SLIDE INDEX

  1. 1. Introduction
  2. 2. Lecture structure
  3. 3. Hallmarks of cancer
  4. 4. Colorectal carcinoma
  5. 5. Caecal polyps at different stages of development
  6. 6. The challenge faced by targeted chemotherapy
  7. 7. Gene therapy providing cells with new ways to die
  8. 8. Advanced cancer is a bodywide disease
  9. 9. Systemic delivery of cancer gene therapy
  10. 10. Blood supply to the liver vs. the tumour
  11. 11. The keys to success with gene therapy
  12. 12. Adenovirus
  13. 13. Cancer gene therapy: strategies
  14. 14. P53 supplementation gene therapy
  15. 15. Tumour necrosis factor as an anticancer agent
  16. 16. TNFerade
  17. 17. TNFerade: phase 1 trial
  18. 18. TNFerade: phase 3 trial
  19. 19. Virotherapy
  20. 20. Lytic viruses: candidates for virotherapy
  21. 21. Why use oncolytic viruses?
  22. 22. Clinical trials with wild type viruses
  23. 23. Why tumours are permissive for wild type viruses
  24. 24. Interferon normally defends cells against viruses
  25. 25. Viruses turn off PKR to make cell “permissive”
  26. 26. Tumours with Ras mutation have inactivated PKR
  27. 27. Mechanism of tumour selectivity of Reovirus
  28. 28. Options for virotherapy
  29. 29. Adenovirus structure & mechanism of infection
  30. 30. The ‘Onyx virus’ (015) lacks E1B55kD
  31. 31. ONYX-015 - a replication selective adenovirus
  32. 32. Oncolytic virotherapy with an Adenovirus (1)
  33. 33. Oncolytic virotherapy with an Adenovirus (2)
  34. 34. Oncolytic virotherapy: TEM image
  35. 35. Oncolytic virotherapy: approved in China
  36. 36. ColoAd1: virotherapy designed by bioselection
  37. 37. Genetic characterisation of ColoAd1
  38. 38. ColoAd1 is active in whole human blood
  39. 39. Viruses can produce therapeutic proteins
  40. 40. Targeted expression of biological therapies
  41. 41. Oncolytic vaccinia virus (Jx594)
  42. 42. Activity of mutant virus in normal cells
  43. 43. Activity of mutant vaccinia virus in tumour cells
  44. 44. Clinical trial of Jx594 in liver cancer
  45. 45. OncoVEX GM-CSF
  46. 46. Phase 3 Talimogene Laherparepvec (T-VEC) trial
  47. 47. Future of cancer virotherapy
  48. 48. END

RELATED TALKS

Play 'Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy'
Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy More info
Dr. Alessandra Biffi

TOPICS COVERED IN THIS TALK

  • Metachromatic Leukodystrophy (MLD)
  • Hematopoietic stem cell therapy (HCT) for lysosomal storage disorders (LSDs)
  • Improving HCT efficacy
  • The role of brain pre-conditioning
  • Mechanisms of microglia turnover
  • Gene therapy (GT) & enzyme release
  • Gene therapy in murine models
  • HSC gene therapy for MLD
  • Lentivirus integration site analysis
  • Stem cells analysis
  • ARSA activity and delivery to the CNS
  • Cerebral and peripheral demyelination
  • Motor function testing (GMFM)
Play 'Gene therapy for the muscular dystrophies'
Gene therapy for the muscular dystrophies More info
Prof. Jeff Chamberlain

TOPICS COVERED IN THIS TALK

  • Introduction to the muscular dystrophies
  • Duchenne muscular dystrophy (DMD)
  • Dystrophin, the gene product of the DMD locus
  • The molecular basis of DMD
  • Strategies for the development of DMD therapies
  • Adeno-associated viral (AAV) vectors and micro-dystrophins
  • Scaling gene therapies to large animal models
  • Exon skipping therapies
Play 'Gene therapy for Hemophilia'
Gene therapy for Hemophilia More info
Prof. Katherine High

TOPICS COVERED IN THIS TALK

  • Hemophilia treatment past and present
  • Gene transfer for genetic disease
  • Viruses engineered to deliver genes
  • Gene therapy using integrating vectors
  • Adeno-associated virus (AAV) structure and composition
  • AAV-Factor IX vectors
  • AAV-mediated gene transfer for hemophilia
  • Risk of germline transmission
  • Peptide library based on AAV and Factor IX
  • Transaminitis and liver enzymes
  • Neutralizing antibodies to AAV
  • Self-complementary DNA and Factor IX synthesis
  • Strategies to overcome immunity to AAV
  • Use of empty capsids
Play 'Helper-dependent adenoviral vectors for gene therapy'
Helper-dependent adenoviral vectors for gene therapy More info
Prof. Nicola Brunetti-Pierri

TOPICS COVERED IN THIS TALK

  • Overview of gene therapy vectors
  • Helper-Dependent Ad (HDAd) vector
  • Liver and lung directed gene therapy
  • Hemophilia B gene therapy
  • OTC deficiency clinical trial
  • Balloon occlusion catheter-based delivery of HDAd
  • HDAd-mediated CF gene therapy
  • Brain gene therapy
  • HDAd as genetic vaccine
  • HDAd and stem cells
Play 'Gene therapy and gene transfer: vector integration preferences and integration site analysis'
Gene therapy and gene transfer: vector integration preferences and integration site analysis More info
Prof. Frederic Bushman

TOPICS COVERED IN THIS TALK

  • Introduction: human gene therapy with integrating vectors
  • Methods for monitoring gene transfer
  • HIV integration targeting
  • Gammaretroviral integration targeting
  • Analysis of vector integration in human gene therapy

USE THIS TALK IN YOUR COURSE

TALK'S CITATION

Seymour, L. (2014), "Gene therapy and virotherapy in the treatment of cancer", in Naldini, L. (ed.), Gene Transfer and Gene Therapy, The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/?t=BL1843833)

RELATED SERIES

The Legacy of Drosophila Genetics
From 'defining the gene' to 'analyzing genome function'
Gene-Environment Interactions
Role in the Modulation of Pulmonary and Autoimmune Disease Risks
Eukaryotic Gene Regulation
From Chromatin to Transcription to mRNA Processing
Antibiotic Resistance
From genes to global prevalence
Cancer Therapy
Latest thinking in efficacy and toxicity
Welcome, Guest
Login  
Apply for Free Trial Recommend to Librarian Keep Me Updated

ABOUT THIS TALK

Speaker(s)

Prof. Leonard Seymour Show Biography

SPEAKER BIOGRAPHY

Prof. Leonard Seymour – University of Oxford, UK

Professor Leonard Seymour is Professor of Gene Therapies, Director of the Clinical Pharmacology Section within the Department of Oncology, and Head of the Cancer Research UK Medicinal Virology Group at the University of Oxford. His overarching research interest lies in combining an understanding of key aspects of genetic engineering with principles of chemistry and pharmaceutics, enabling design and translational development of innovative strategies for treatment of cancer and other diseases. With interests predominantly in viral therapeutics, he leads an integrated research group with expertise ranging from molecular virology and immunology through cell biology to pharmaceutical and polymer chemistry, with a strong translational ethos to engender early phase clinical studies. He is a scientific founder and former Board member of Hybrid Biosystems Ltd which, in 2010, merged with Myotec Therapeutics Ltd to became PsiOxus Therapeutics, a biotechnology company that produces novel therapeutics particularly for cancer treatment and which is currently conducting a series of clinical trials exploring intravenous delivery of oncolytic viruses for treatment of advanced cancer. In 2012 he was a founding scientist of Oxford Genetics Ltd, a plasmid company developing a modular approach to molecular cloning in order to improve the efficiency of genetic engineering and synthetic biology. Professor Seymour is also the Secretary General and Trustee of the European Society of Gene and Cell Therapy and an Executive Council Member of the International Society for Cell and Gene Therapy of Cancer. He has supervised over 30 PhD students, has filed 12 patents and published more than 150 primary scientific papers.

Publication Date

November, 2014

Topics Covered

Mutations and microenvironment in cancer... more

TOPICS COVERED IN THIS TALK

  • Mutations and microenvironment in cancer
  • The challenge of cancer gene therapy
  • Cancer gene therapy strategies: p53 and TNF
  • Virotherapy against tumour cells
  • Virotherapy studies with wild-type vs. genetically-engineered viruses (Adenovirus, Vaccinia & Herpes)
  • Future of cancer virotherapy

Series

Gene Transfer and Gene Therapy

OTHER TALKS IN THIS SERIES

PRINCIPLES AND GENERAL THEMES
Play '1. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 1 of 2'
1. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 1 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Gene therapy
  • Key elements in gene transfer
  • Viral infection
  • Cell entry
  • Viral replication
  • Creating a viral vector
  • Therapeutic activity
  • Therapeutic activity after cell division
  • Clinical gene therapy: ex vivo and in vivo milestones
  • Advancing gene therapy: the challenges
  • Limitations of expression cassette
  • Properties & limitations of transfer vector
Play '2. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 2 of 2'
2. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 2 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Hazards of transfer vectors
  • Acute exposure to vector particles
  • Hazards for viral and integrating vectors
  • Immune responses to gene transfer (to vector components and to transgene product
  • Types of gene transfer vectors/systems (viral and non-viral)
  • Challenges to clinical translation
Play '3. Manufacturing viral gene therapy vectors: general approaches and challenges'
3. Manufacturing viral gene therapy vectors: general approaches and challenges More info
Prof. John T. Gray
UG 

TOPICS COVERED IN THIS TALK

  • Manufacturing of Viral Gene Therapy Vectors
  • Different types of vector production systems
  • Concepts for the design of viral vector production cells
  • Specific viral vector production systems for adenovirus, adeno-associated virus, gamma-retrovirus, and lentivirus
  • Downstream processing
  • Regulatory considerations
Play '4. The host response: adaptive immune response to viral vector delivery'
4. The host response: adaptive immune response to viral vector delivery More info
Prof. Roland W. Herzog
UG 

TOPICS COVERED IN THIS TALK

  • Gene therapy using viral vector
  • Risk of immune responses specific to vector or transgene product
  • Pre-existing immunity to viral vectors due to natural infection
  • Design of vectors to minimize or entirely avoid B and T cell responses
  • Modification of gene transfer protocols to minimize/avoid/circumvent B and T cell responses
MAJOR GENE TRANSFER PLATFORMS AND GENE THERAPY STRATEGIES
Play '5. Gammaretroviral vectors: biology, design and applications'
5. Gammaretroviral vectors: biology, design and applications More info
Prof. Axel Schambach
UG 

TOPICS COVERED IN THIS TALK

  • The biology of retroviruses: genome & particle organization, retroviral life cycle
  • Retroviruses as evolutionary adapted vehicles to deliver genetic information
  • From the virus to the retroviral vector
  • Effective gene therapy in the clinical arena
  • Adverse events and prevention of insertional mutagenesis
  • SIN vectors and the right therapeutic window for gene therapy
  • Developing retroviral intermediates as delivery tools
  • A time journey in the field of retroviral gene therapy
Play '6. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 1 of 2'
6. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 1 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Properties of retroviral vectors: Genetic stability in target cells, Transgene expression, Fidelity of replication, Target cell spectrum, Transdution efficiency, Toxicity, RCR or WT virus contamination, Integration, Immunogenicity
  • Innate immune recognition of retroviral vectors
  • Lentiviral vectors
  • Nuclear import of viral genome
  • Challenges of developing lentiviral vectors
  • Viral vector design
  • Design of HIV-based vectors
  • Third generation lentiviral vectors
  • Lentiviral vector composition
  • Lentiviral gene transfer
  • Reducing HIV content of packaging system
  • Self-inactivating transfer vectors
  • HIV vector transcription in HIV-1 infected cells
  • Lentiviral vector biosafety
  • Lentiviral vectors: risk of insertional mutagenesis
Play '7. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 2 of 2'
7. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 2 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Lentiviral vectors: applications, gene transfer efficiency and transgene expression
  • Therapeutic potential of HSC gene therapy
  • Vector integration site analysis
  • Lentiviral-mediated HSC gene transfer
  • Rationale for HSC gene therapy vs. BMT
  • HSC gene transfer by LV: current issues
  • Restriction factors for lentiviral gene transfer
  • Ex vivo transduction by lentiviral vectors
  • HSC gene transfer by LV: current goals
  • Applications: ex vivo into hematopoietic stem cells, ex vivo into lymphocytes, In vivo gene transfer (liver and CNS)
  • Systemic delivery of LV: current issues
  • Direct LV injection into the CNS
  • CNS gene transfer: current issues
Play '8. Gene therapy and gene transfer: vector integration preferences and integration site analysis'
8. Gene therapy and gene transfer: vector integration preferences and integration site analysis More info
Prof. Frederic Bushman

TOPICS COVERED IN THIS TALK

  • Introduction: human gene therapy with integrating vectors
  • Methods for monitoring gene transfer
  • HIV integration targeting
  • Gammaretroviral integration targeting
  • Analysis of vector integration in human gene therapy
Play '9. Surface-mediated targeting of lentiviral vectors'
9. Surface-mediated targeting of lentiviral vectors More info
Prof. Dr. Christian Buchholz

TOPICS COVERED IN THIS TALK

  • In vivo and ex vivo gene therapy
  • Cell entry modes of retroviral vectors
  • Molecular functions of viral envelope proteins
  • Introduction to surface targeting
  • Targeting subtypes of lymphocytes and hematopoietic stem cells (Ex vivo)
  • In vivo targeting (local vs. systemic administration)
Play '10. Tracking vector insertion sites to explore the biology of transduced cells in vivo'
10. Tracking vector insertion sites to explore the biology of transduced cells in vivo More info
Prof. Dr. Christof Von Kalle

TOPICS COVERED IN THIS TALK

  • Clonal marking by integrating vectors
  • Integration site analysis by LAM-PCR
  • Analysis of gene therapy clinical trials for X-SCID, X-CGD, ADA-SCID & Cancer
  • Avoiding oncogenesis in gene therapy
  • Gene therapy for Wiskott-Aldrich Syndrome (WAS)
  • Characterization & understanding of pathogenesis
  • Integrations in known proto-oncogenes
  • Possible triggers of AML development
  • Safer vector systems & new technologies
  • Lentiviral SIN-vectors
  • Influence of vector type on clinical outcome
  • LV integration site analysis: X-ALD trial
  • Repopulation of hematopoietic system
  • Targeted genome modification: nucleases
  • Specificity of DNA modification by ZFN
  • The TALEN nuclease and how it performs
Play '11. Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy'
11. Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy More info
Dr. Alessandra Biffi

TOPICS COVERED IN THIS TALK

  • Metachromatic Leukodystrophy (MLD)
  • Hematopoietic stem cell therapy (HCT) for lysosomal storage disorders (LSDs)
  • Improving HCT efficacy
  • The role of brain pre-conditioning
  • Mechanisms of microglia turnover
  • Gene therapy (GT) & enzyme release
  • Gene therapy in murine models
  • HSC gene therapy for MLD
  • Lentivirus integration site analysis
  • Stem cells analysis
  • ARSA activity and delivery to the CNS
  • Cerebral and peripheral demyelination
  • Motor function testing (GMFM)
Play '12. Directed evolution of novel adeno-associated viral vectors for gene therapy'
12. Directed evolution of novel adeno-associated viral vectors for gene therapy More info
Prof. David Schaffer
UG 

TOPICS COVERED IN THIS TALK

  • Recent successes in gene therapy
  • Problems in the field with naturally derived vectors
  • Directed evolution as an approach to engineer optimal viral vector variants that meet clinical needs
  • Examples: development of variants to evade neutralizing antibodies and evolution for enhanced delivery in the retina
Play '13. Gene therapy for Hemophilia'
13. Gene therapy for Hemophilia More info
Prof. Katherine High

TOPICS COVERED IN THIS TALK

  • Hemophilia treatment past and present
  • Gene transfer for genetic disease
  • Viruses engineered to deliver genes
  • Gene therapy using integrating vectors
  • Adeno-associated virus (AAV) structure and composition
  • AAV-Factor IX vectors
  • AAV-mediated gene transfer for hemophilia
  • Risk of germline transmission
  • Peptide library based on AAV and Factor IX
  • Transaminitis and liver enzymes
  • Neutralizing antibodies to AAV
  • Self-complementary DNA and Factor IX synthesis
  • Strategies to overcome immunity to AAV
  • Use of empty capsids
Play '14. Gene therapy for the muscular dystrophies'
14. Gene therapy for the muscular dystrophies More info
Prof. Jeff Chamberlain

TOPICS COVERED IN THIS TALK

  • Introduction to the muscular dystrophies
  • Duchenne muscular dystrophy (DMD)
  • Dystrophin, the gene product of the DMD locus
  • The molecular basis of DMD
  • Strategies for the development of DMD therapies
  • Adeno-associated viral (AAV) vectors and micro-dystrophins
  • Scaling gene therapies to large animal models
  • Exon skipping therapies
Play '15. Helper-dependent adenoviral vectors for gene therapy'
15. Helper-dependent adenoviral vectors for gene therapy More info
Prof. Nicola Brunetti-Pierri

TOPICS COVERED IN THIS TALK

  • Overview of gene therapy vectors
  • Helper-Dependent Ad (HDAd) vector
  • Liver and lung directed gene therapy
  • Hemophilia B gene therapy
  • OTC deficiency clinical trial
  • Balloon occlusion catheter-based delivery of HDAd
  • HDAd-mediated CF gene therapy
  • Brain gene therapy
  • HDAd as genetic vaccine
  • HDAd and stem cells
Play '16. HSV vectors: approaches to the treatment of chronic pain'
16. HSV vectors: approaches to the treatment of chronic pain More info
Prof. Joseph C. Glorioso

TOPICS COVERED IN THIS TALK

  • HSV gene therapy for pain
  • Criteria for vector engineering and gene delivery
  • HSV gene expression and HSV vectors
  • Treating pain with opioid peptides
  • Spinal nerve ligation model of neuropathic pain
  • Transduction of lumbar DRG with HSV vector
  • Osteolytic sarcoma studies
  • Clinical trial in terminal cancer patients
  • Effect of glycine on nociceptive behavior
  • Selective vector infection and expression
  • Targeting transgene expression with promoters
  • Gene expression constructs
  • Promoter-regulated expression in embryonic DRG
  • Comparing LAP, CMV & CGRP gene expression
Play '17. Turning genomic junk into treasure: genetic engineering with the Sleeping Beauty transposon system'
17. Turning genomic junk into treasure: genetic engineering with the Sleeping Beauty transposon system More info
Dr. Zoltan Ivics

TOPICS COVERED IN THIS TALK

  • Transposons can be viewed as natural DNA transfer vehicles
  • Transposons are capable of efficient genomic insertion, similar to integrating viruses
  • Transposition can be controlled by conditionally providing the transposase enzyme
  • DNA of interest cloned into a transposon-based vector can be utilized for stable genomic insertion in a regulated and highly efficient manner
  • Transposition opens up many avenues for genome manipulations in vertebrates
  • Generation of transgenic cells and germline-transgenic animals using transposons
  • The Sleeping Beauty synthetic transposon
  • Clinical applications of the Sleeping Beauty system
Now Playing
NEW TECHNOLOGIES FOR SEQUENCE-SPECIFIC EDITING OF GENE EXPRESSION
Play '19. RNAi for neurological diseases'
19. RNAi for neurological diseases More info
Prof. Beverly L. Davidson

TOPICS COVERED IN THIS TALK

  • Repeat expansion diseases
  • Polyglutamine (polyQ) repeat diseases
  • Huntington’s disease
  • Vectors for delivering genetic material to brain
  • AAVs for delivering RNAi for reducing gene expression
  • Artificial miRNAs
  • Testing miHD for efficacy
  • Off-target silencing
  • MRI-guided delivery of AAV into primates
  • HTT suppression
  • Other gain-of function diseases
  • Targeted infusion for broad coverage
  • Silencing ataxin-1
  • Nonallele specific silencing: experimental design
  • Expression and activity of miSCA1

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.